Deciphera Pharmaceuticals, Inc.

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

The European Medicines Agency has begun reviewing a new batch of products for potential pan-EU marketing approval, including vimseltinib and a recombinant pertussis vaccine (RPV), both of which could

After a strong start to biopharma merger-and-acquisition activity in the first quarter of 2024, transactions declined notably in the second quarter, according to data provided by Evaluate. The second

The cash keeps coming into SynOx Therapeutics Ltd. , with the Ireland-domiciled biotech securing over $100m in the past week to push its late-stage asset emactuzumab over the regulatory finishing lin